

- 2:15 147. Boron Modified Peptide: a Novel Dissociative Inhibitor of HIV-1 Protease. A.D. Pivazyán and W.H. Prusoff. *Yale University, New Haven, CT, USA.*
- 2:30 148. Factors Other Than Reverse Transcriptase Contribute to Resistance of Feline Immunodeficiency Virus to Reverse Transcriptase-Targeted Antivirals. T.W. North, K.M. Remington, Y.-Q. Zhu, R.A. Smith, and D.G. McBroom. *University of Montana, Missoula, MT, USA.*
- 2:45 149. Long Term Suppression of Human Immunodeficiency Virus Type 1 Activity In Vitro by Guanosine/Thymidine Oligonucleotides (GTOs). R.F. Rando, J. Ojwang, A. Elbaggari, G.R. Reyes, K. Jayaraman, and M.S. McGrath. *Triplex Pharmaceutical Corporation, The Woodlands, TX; and University of California at San Francisco, San Francisco General Hospital, San Francisco, USA.*
- 3:00 150. Development of an In Vivo Model of HIV Latency and Activation. P.M. Feorino, S.T. Butera, J.R. Mead, T.M. Folks, and R.F. Schinazi. *VA Medical Center, Emory University, Decatur, GA; and Centers for Disease Control and Prevention, Atlanta, GA, USA.*
- 3:15 151. Use of Fluorescent Tracking Dye PKH26 to Follow the Fate of HIV-Infected Human PBMC in SCID Mice: An In Vivo Model for AIDS Drug Development. P.L. Black, D.D. Broud, O.L. Wood, G.P. Goldberg, and M.A. Ussery. *FDA, Rockville, MD, USA.*
- 3:30 152. HIV-Infected Hu-PBMC-SCID Mice as Model for Antiviral Drug Development. M.A. Ussery, D.D. Broud, O.L. Wood, and P.L. Black. *FDA, Rockville, MD, USA.*
- 3:45 153. Brain Delivery of 2'-F-ara-ddI by Utilizing Xanthine Oxidase Biotransformation System. C.K. Chu, T. Koudriakova, K. Shanmuganathan, L. Ni, F.D. Boudinot, J.M. Gallo, and R.F. Schinazi. *University of Georgia, Athens, GA; and Emory University School of Medicine, VAMC, Atlanta, GA, USA.*

Poster Session III: Hepadnavirus, Respiratory Virus, and Other Infections

4:30-6:30pm

154. Priming of Duck Hepatitis B Virus DNA Replication: A Viral Function Which is Refractory to Inhibition by Triphosphates of Dideoxynucleoside Analogs. K.A. Staschke, A.J. Schilke, and J.M. Colacino. *Lilly Research Laboratories, Indianapolis, IN, USA.*
155. Synthesis and Antiviral Activity of Novel Tricyclic Analogues of Acyclovir and Ganciclovir. B. Golankiewicz, T. Ostrowski, G. Andrei,

R. Snoeck, and E. De Clercq. *Polish Academy of Sciences, Poznan, Poland, and Katholieke Universiteit Leuven, Leuven, Belgium.*

156. Synthesis and Study of Structural and Acyclic 6-Azacytidine Analogues and Their Substituted Derivates. A.S. Shalamay, I.V. Alexeeva, L.G. Palchikovska, L.V. Nosach, and N.S. Dyachenko. *Ukrainian Academy of Sciences, Kiev, Ukraine.*
157. Study of Chinese Herbal Drugs Against Cocksackie B1, B3, B4 Virus in Cell Culture. T.-M. Zhang, Z.-J. Hu, and M.-Y. Zhang. *Hubei Medical University, Wuhan, Hubei, PRC.*
158. Study of Chinese Herbal Drugs Against Epidemic Hemorrhagic Fever Virus in Cell Culture. T.-M. Zhang, Z.-J. Hu, and G. Lie. *Hubei Medical University, Wuhan, Hubei, PRC..*
159. Pharmacologically Active Amines as In Vitro Inhibitors of Junin Virus. E.B. Damonte, S.E. Mersich, N.A. Candurra, L. Maskin, and V. Castilla. *Universidad de Buenos Aires, Buenos Aires, Argentina.*
160. The Effect of Some Drugs on Proteolytic Processing of Adenoviral Proteins. L.N. Nosach, N.S. Dyachenko, S.I. Butenko, V.L. Zhovnovataya, L.I. Shevchenko, and M.A. Lozinsky. *Ukrainian Academy of Sciences, Kiev, Ukraine.*
161. The Effect of some Nucleoside Analogues on Reproduction of Adenoviruses. N.S. Dyachenko, L.N. Nosach, V.L. Zhovnovataya, S.I. Butenko, I.V. Alekseeva, A.S. Shalamay, M.Y. Lidak, T.L. Tsilevich, and V.L. Florentiev. *Ukrainian Academy of Sciences, Kiev, Ukraine; Latvian Academy of Sciences, Riga, Latvia; and Russian Academy of Sciences, Moscow, Russia.*
162. β -L-2',3'-Dideoxycytidine (L-DDC) and its 5-Fluoro Derivative (L-FDDC) are Potent Inhibitors of Hepatitis B Virus (HBV). R.F. Schinazi, J.-P. Sommadossi, G. Gosselin, and J.-L. Imbach. *VA Medical Center, Emory University, Decatur, GA; University of Alabama, Birmingham, AL, USA; and University of Montpellier II, Montpellier, France.*
163. Antiviral Drug Izatizon Restores Interferon Action. The Enlargement of Interferon Antiviral Activity Spectrum. Yu.V. Patskovsky, T.P. Voloschuk, V.V. Gaiduk, E.N. Negrebetskaja, S.L. Rybalko, O.Yu. Zakhartsev, and A.I. Potopalsky. *Institute of Molecular Biology and Genetics, Kiev; and L.V. Gromashevsky Research Institute of Epidemiology and Infective Diseases, Kiev, Ukraine.*

164. Antiviral Action of Glutathione: Study on the Mechanism. A.T. Palamara, M.R. Ciriolo, C. Bu, R. Luglio, P. Di Francesco, C. Favalli, G. Rotilio, and E. Garaci. *University of Rome "Tor Vergata", Rome, Italy.*
165. Effect of Fialuridine (FIAU) on the In Vitro Replication of Mitochondrial DNA in Human T Cells and in Human Hepatoblastoma Cells. J.M. Colacino, S.K. Malcolm, and S.R. Jaskunas. *Lilly Research Laboratories, Indianapolis, IN, USA.*
166. A Rapid and High Capacity In Vitro Antiviral Assay for Hepatitis B Virus Using Quantitative Polymerase Chain Reaction (PCR). R.M. Lloyd, Jr., J.T. Huong, A. McMillan, and R.F. Schinazi. *Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Ga, USA.*
167. Inhibition of HBV Polymerase by Nucleotide Analogs: Differential Activity of Enantiomers. M.G. Davis, S.L. Smith, J.E. Wilson, A. Aulabaugh, S.M. Daluge, N.A. VanDraanen, F.L. Boyd, W.H. Miller, and J.M. Cullen. *Burroughs Wellcome Co., Research Triangle Park, NC; and College of Veterinary Medicine, NCSU, Raleigh, NC, USA.*
168. Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity. L. Kucera, C. Fowler, N. Iyer, C. Whang, S. Morris-Natschke, K. Ishaq, and C. Piantadosi. *Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; and University of North Carolina, Chapel Hill, NC, USA.*
169. The Inhibition of Flavivirus RNA Synthesis by the Heteropolyanion HPA-23 and Related Compounds in the In Vitro RNA-Dependent RNA Polymerase Assay. A. Bartholomeusz, P.J. Wright, E. Tomlinson, S. Locarnini, C. Birch, H. Weigold, S. Marcuccio, and G. Holan. *Monash University, Clayton; Fairfield Hospital, Fairfield; and CSIRO, Australia.*
170. Inhibition of Duck Hepatitis B Virus Replication by N-(phosphonoacetyl)-L-Aspartate (PALA; USNUS-08-0) In Vitro. T. Shaw, S.A. Locarnini, and H.A. Blough. *Fairfield Hospital, Victoria, Australia; and US Bioscience, West Conshohocken, PA, USA.*
171. Studies on some New Biological Properties of Isoprinosine Concerning its Buffer Capacity. S.N. Pancheva, R. Nacheva, and M. Lidaks. *Bulgarian Academy of Sciences, Sofia, Bulgaria; and Latvian Academy of Sciences, Riga, Latvia.*
172. Antiviral Activity of Proteolytic Inhibitor Ambenium (Para-Aminomethyl benzoic Acid). V.P. Lozitsky, A.S. Fedtchouk, Y.I. Gyryla, A.G. Kolomiets, N.D. Kolomiets, V.A. Novitsky, A.Yu. Sudakov, V.P. Buyko, I.N. Fedtchouk, and P.G. Veveritsa. *I.I. Mechnikov Research Institute of Virology and Epidemiology, Odessa, Ukraine.*

173. An Economical MTT-based in vitro Assay System for Bovine Viral Diarrhea Virus (BVDV): A Pestivirus in the Family of Flaviviridae. J.J. Kirs and W.M. Shannon. *Southern Research Institute, Birmingham, AL, USA.*
174. Therapy of Patients with Chronic Viral Infections and Prophylaxy of Diseases' Recurrences by Vaccines. I. Barinsky. *Russian Academy of Medical Sciences, Moscow, Russia.*
175. Seasonal Changes in Metabolism in the Woodchuck Hepatitis Virus Model Affect the Toxicity of the Antiviral Nucleoside Analog FEAU. C.J. Nielsen, B.C. Tennant, A.J. Kempf-Grote, and M.A. Ussery. *DAVDP/Antiviral Research Laboratory, Rockville, MD; and Cornell University, College of Veterinary Medicine, Ithaca, NY, USA.*
176. Bone Marrow Mononuclear Cells Producing IL-1 and IL-2 Inhibited by HBV In Vitro and In Vivo. Z. Wu, K. Xiong, and H. Huang. *Wuhan Institute of Virology Academia Sinica and Union Hospital, Tongi Medical University, China.*
177. Antiviral Activity of 1-Methylascorbigen Against Bunraviral Infections (In Experimental). L.K. Berezina, M.N. Preobrazhenskaya, and D.K. Lvov. *Russian Academy of Medical Sciences, Moscow, Russia.*
178. Effect of Ribavirin on SSPE Virus Infection in Hamsters. M. Hosoya, Y. Honda, H. Suzuki, and S. Shigeta. *Fukushima Medical College, Fukushima, Japan.*
179. Determination of Functional Domains in the influenza Virus Polymerase through Site-Directed Mutagenesis and Transient Expression. J. Matthews, O. Gecha, L. Tiley, G. Luo, T. Chung, C. Cianci, M. Hagen, and M. Krystal. *Bristol-Myers Squibb PRI, Princeton, NJ, USA.*
180. Antisense Inhibition of Respiratory Syncytial Virus Replication. R.E. Kilkuskie, P. Brown, H.A. Hamlin, D. Walther, J. Goodchild, and A.K. Field. *Hybridon, Inc., Worcester, MA, USA.*
181. Synthetic Peptides as Analogs of the Adenovirus Capsid Protein Epitopes and Possible Immunotherapeutical Preparations. L.A. Tarassishin. *Ukrainian Academy of Sciences, Kiev, Ukraine.*
182. A Wide Spectrum of Antiviral Activity of a New Syntetic Inhibitor of Proteolysis. M.O. Lozinski, V.P. Lozitski, L.I. Shevchenko, T.A. Tatarova, A.G. Kolomiets, P.G. Rytic, N.D. Kolomiets, G.V. Vladkyo, A.S. Fedtchouk, and Y.I. Girlya. *Academy of Sciences of Ukraine, Kiev, Ukraine; Ministry of Health of Ukraine, Odessa, Ukraine; and Byelarus Research Institute of Epidemiology and Microbiology, Minsk, Republic Byelarus.*

183. Inhibition of Respiratory Syncytial Virus Replication In Vitro by N-butyldeoxynojirimycin (NB-DNJ/SC-48334). S.P. Tucker, T.R. Stiebel, Jr., and M.L. Bryant. *Searle Research and Development, St. Louis, MI, USA.*
184. Anti-Influenza Virus Activity of 4-Guanidino-2, 4-Dideoxy-2, 3-Dehydro-N-Acetylneuraminic Acid In Vitro. F. Hayden, B. Rollins, and L. Madren. University of Virginia, Charlottesville, VA, USA.
185. First Phase of Clinical Trials New Antiviral Drug-Viramid. O.I. Kubar, M.A. Bichurine, L.S. Safonova, L.A. Stepanova, O.V. Paskonkina, S.L. Firsov, L.E. Nikitina, and I.A. Boikov. *Pasteur Institute, St. Petersburg, Russia.*
186. Identification of a Novel Class of Oligonucleotide Inhibitors of the Influenza Viral Polymerase. T.D.Y. Chung, C. Cianci, M. Hagen, B. Terry, J.T. Matthews, M. Krystal, and R.J. Colonno. *Bristol-Myers Squibb PRI, Princeton, NJ, USA.*
187. The Study of Effect of a New Antiviral Drug Arbidol on Different Stages of Viral Reproduction. I.A. Leneva, N.I. Fadeeva, and I.T. Fedykina. *Chemical and Pharmaceutical Institute, Moscow, Russia.*
188. Antiviral Activity of Mizoribine(4-Carbamyl-1-B-D-Ribofuranosylimidazolium-5-olate) Against Ortho- and Paramyxoviruses. Y. Kosugi, Y. Saito, S. Mori, M. Hosoya, M. Baba, and S. Shigeta. *Fukushima Medical College, Fukushima; and Asahi Chemical Industry Co., Ltd., Ohito, Shizuoka, Japan.*
189. Selective Inhibition of Myxovirus Replication by a Novel Series of Cholesterol-Naphthalenesulfonic Acid Hybrid Molecules. S. Ikeda, M.F. Wong, P. Mohan, and E. De Clercq. *Katholieke Universiteit Leuven, Leuven, Belgium; and University of Illinois at Chicago, IL, USA.*
190. Inhibition of Influenza Virus Reproduction by Combined Preparations of Medicinal Plants. J. Serkedjieva. *Bulgarian Academy of Sciences, Sofia, Bulgaria.*
191. Protective Effect of Bacterial Preparation CM in Experimental Influenza Infection. J. Serkedjieva and E. Ivanova. *Bulgarian Academy of Sciences, Sofia, Bulgaria.*
192. Combination Effects of Picornavirus Replication Inhibitors. L. Nikolaeva and A.S. Galabov. *Bulgarian Academy of Sciences, Sofia, Bulgaria.*
193. Study of Chinese Herbal Drugs Against Respiratory Syncytial Virus in Cell Cultures. T.-M. Zhang, Z.-J. Hu, and G. Nie. *Hubei Medical University, Wuhan, Hubei, PRC.*

194. Combined Antiviral Effect of Some Bacterial and Synthetic Inhibitors. A.G. Uzunova. *Bulgarian Academy of Sciences, Sofia, Bulgaria.*
195. Proteolysis Inhibitors Influence on the Interactions of Influenza Viruses with Membranes of Sensitive Cells. V.P. Lozitsky, A.S. Fedtchouk, and Yu.I. Girlya. *Research Institute of Virology and Epidemiology, Odessa, Ukraine.*
196. Aprotinin Treatment of Influenza B Virus Bronchopneumonia of Mice. P.B. Golyando, A.V. Ovcharenko, and O.P. Zhirnov. *The D.I. Ivanovsky Virology Institute, Moscow, Russia.*
197. Combined Effect of an Antioxidative Agent (Ionol) and Rimantadine on Experimental Influenza Virus A(H3N2) Infection in Mice. A.S. Galabov, V. Savov, G. Koinova, L.K. Chetverikova, V. Hadjiathanassova, T.A. Kramskaya, and M. Behar. *Bulgarian Academy of Sciences, Sofia; St. Kliment Ohridski University of Sofia, Bulgaria; and Russian Academy of Medical Sciences, St. Petersburg, Russia.*
198. In Vitro and In Vivo Inhibition of Ortho- and Paramyxovirus Infection by a New Class of Sulfonic Acid Polymers Interacting with Virus-Cell Binding and/or Fusion. S. Ikeda, S. Verma, P. Mohan, J. Neyts, and E. De Clercq. *Katholieke Universiteit Leuven, Leuven, Belgium; and University of Illinois at Chicago, IL, USA.*
199. Antiviral Effect of BC30 in Experimental Influenza Virus Infection in White Mice. A.G. Uzunova. *Bulgarian Academy of Sciences, Sofia, Bulgaria.*
200. Inhibition of Virus Infections of Mice by the Combination of Aerosolized MnSOD and Ribavirin. R.W. Sidwell, V.R. Moss, J.H. Huffman, R. Nimrod, and A. Panet. *Utah State University, Logan, UT, USA; and Biotechnology General, Rehovot, Israel.*
201. Single Dose Efficacy of 2'-fluorodeoxyguanosine in the Mouse and Ferret Influenza Models. M. Tisdale, D. Lowe, J. Stables, K.J. Jakeman, and C. Sweet. *The Wellcome Research Laboratories, Beckenham, Kent; and University of Birmingham, Birmingham, U.K.*
202. The New Adamantane Derivative Inhibiting DNA-Viruses Reproduction. E.I. Boreko, O.T. Andreeva, G.V. Vladyko, S.N. Nikolaeva, Yu.N. Klimochkin, L.V. Korobchenko, V.A. Rusyaev, E.A. Izergina, I.K. Moiseev, and V.I. Votyakov. *Byelorussian Research Institute for Epidemiology and Microbiology, Minsk, Republic of Byelorussia.*
203. Toxicity of Aerosolized Aprotinin in Animals. A.V. Ovcharenko, P.B. Golyando, O.P. Zhirnov, T.P. Svinogeeva, G.V. Dolgova, and A.V. Nikitin. *The D.I. Ivanovsky Virology Institute, and State Research Center of Antibiotics, Moscow, Russia.*

204. Guinea Pig as a Model for Study of Marburg Virus Interaction with Mononuclear Phagocytes. A.A. Skripchenko, E.I. Rjabchikova, and A.M. Shestopalov. *Institute of Molecular Biology SPA "Vector", Koltsovo, Novosibirsk Region, Russia.*
205. Role of Nonspecific Factors of Immunity in Treatment of Experimental Arenaviral Hemorrhagic Fever. G.M. Ignatyev, S.A. Kaliberov, A.V. Tverdokhlebov, and I.V. Patrusheva. *Institute of Molecular Biology SPA "Vector", Koltsovo, Novosibirsk Region, Russia.*
206. Theoretical Foundation Optimal Design Criteria of Antiviral Preparations. V.A. Zhukov and V.M. Chermashentsev. *Institute of Molecular Biology SPA "Vector", Koltsovo, Novosibirsk Region, Russia.*